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ABSTRACT 
Background and Objectives: Triple anti-platelet therapy is known to prevent restenosis after drug-eluting stent (DES) 
implantation. However, there is little available data concerning the efficacy of triple anti-platelet therapy for acute 
myocardial infarction (AMI). Subjects and Methods: We analyzed 528 consecutive patients with AMI undergoing 
DES implantation between Nov 2005 and Apr 2008. We compared clinical outcomes in the triple anti-platelet 
therapy (group I, n=413: cilostazol combined with aspirin and clopidogrel for at least one month) and dual anti-
platelet therapy groups (group II, n=115: aspirin and clopidogrel). Results: There were no significant differences in 
baseline characteristics. However, ST elevation myocardial infarction (STEMI) and use of TAXUS
® stents were 
more common (70.9% vs. 55.7%, p=0.002; 83.5% vs. 73.0%, p=0.011) in Group I. Group I had lower incidences of 
cardiac death, 6-month target lesion revascularization (TLR), and major adverse cardiac and cerebrovascular events 
(MACCE) compared to Group II (1.7% vs. 5.7%, p=0.022; 5.7% vs. 11.5%, 0.035; 7.9% vs. 16.0%, p=0.011). On 
subgroup analysis, the incidence of 6-month TLR was lower among patients with American College of Cardiology/ 
American Heart Association (ACC/AHA) B2 or C lesions and non-STEMI (6.0% vs. 14.9%, p=0.012; 4.3% vs. 
19.1%, p=0.002) in Group I compared to those in Group II. The rates of bleeding complications were no different 
between the two groups. On multivariate analysis, Killip III or IV and triple anti-platelet therapy were independent 
predictors of 6-month MACCE {hazard ratio (HR)=3.382; 95% confidence interval (CI)=1.384-8.262, HR=0.436; 
95% CI=0.203-0.933}. Conclusion: Triple anti-platelet therapy is safe and efficacious, and it prevents TLR in patie-
nts with AMI, especially those with complex lesions and non-STEMIs. (Korean Circ J 2009;39:190-197) 
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Introduction 
 
Percutaneous coronary intervention (PCI) with drug-
eluting stents (DES) is well known to reduce the re-steno-
sis rate to a significant extent compared to bare-metal 
stents (BMS) in patients with acute myocardial infarction 
(AMI).
1)2) It has been reported, however, that DESs in-
crease the incidence of stent thrombosis as time passes.
3) 
The treatment guidelines from the American College of 
Cardiology/American Heart Association (ACC/AHA) 
recommend that double anti-platelet therapy with aspirin 
and clopidogrel be prescribed for at least 12 months in 
patients who have undergone DES implantation.
4) 
Cilostazol selectively inhibits the action of phospho-
diesterase type 3, and it thereby has various functions, 
such as anti-platelet, vasodilatory, anti-atherosclerotic, 
and anti-proliferative actions. Cilostazol is also known to 
suppress neointimal hyperplasia following stent implan-
tation.
5-7) Recent studies have shown that triple anti-pla-
telet therapy including cilostazol reduces the occurrence 
of stent thrombosis compared to anti-platelet therapy 
based on aspirin and clopidogrel.
8) Triple anti-platelet 
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therapy including cilostazol has also been shown to sig-
nificantly reduce restenosis and target lesion revascula-
rization, particularly in patients with diabetes mellitus.
9)10) 
To date, however, no studies have reported the effect of 
triple anti-platelet therapy in patients with AMI, a high-
risk group for stent thrombosis and re-stenosis. 
The aim of this study was to compare the effectiveness 
of triple anti-platelet therapy with cilostazol with that of 
standard dual anti-platelet therapy in patients with AMI 
who have undergone DES implantation. 
 
Subjects and Methods 
 
Subjects 
We conducted a single-center, retrospective study of 
528 AMI patients who underwent successful TAXUS
® 
or Cypher
® stent implantation at the Heart Center of 
Chonnam National University Hospital during a 30-
month period (November 2005 to April 2008). The mean 
age of these patients was 61.6±11.72 years, and 395 of 
them were men. 
Patients who received cilostazol in addition to standard 
dual anti-platelet therapy following successful stent im-
plantation (aspirin+clopidogrel+cilostazol) were assign-
ed to Group I (n=413), and those who received the 
standard dual anti-platelet therapy (aspirin+clopidogrel) 
were assigned to Group II (n=115). 
 
Percutaneous coronary intervention and medical 
treatment 
In patients with AMI, emergency or early invasive tre-
atments were determined based on patient status, accord-
ing to the clinical decision of the operator. In inter-
ventional treatment, the femoral artery was punctured 
and a 6 or 7-Fr sheath was inserted. Following catheter 
insertion, the procedure was performed using a guide 
wire. DESs were implanted in cases in which coronary 
artery stenoses were present following balloon angioplasty. 
The type of DES was decided by the operator. Success-
ful PCI was defined as a target vessel at the treatment 
site with antegrade thrombolysis in myocardial infarction-
3 (TIMI-3) flow and angiographic residual stenosis less 
than 50% following stent implantation. Anti-platelet 
agents were administered to all patients prior to inter-
vention: aspirin 300 mg and clopidogrel 300-600 mg. 
Standard post-intervention treatment was aspirin 100 mg 
for life and clopidogrel 75 mg for at least one year. In 
accordance with the subjective decision of each operator, 
cilostazol was given to patients at a daily dose of 200 mg 
for at least one month. 
Other medical treatments, including angiotensin-con-
verting enzyme inhibitors, beta-blockers, calcium channel 
blockers, and lipid-lowering agents, were also used in a 
non-restrictive manner based on the standard treatment 
regimen for patients with AMI. 
Clinical outcomes 
Patients were told to visit the outpatient clinic one 
month after discharge and every two to three months 
thereafter on a regular basis. In “lost to follow-up” cases, 
specialized personnel monitored the clinical course by 
means of a telephone call. We measured the incidences 
of target lesion revascularization (TLR), cardiac death, 
non-fatal myocardial infarction, coronary artery bypass 
graft, major adverse cardiac and cerebrovascular accident 
(MACCE), bleeding, and stent thrombosis in all patients 
within the 6-month period after the procedure. TLR was 
defined as any percutaneous revascularization performed 
on the treated segment. Myocardial infarction was defin-
ed as a rise or fall in troponins (with at least one value 
above the 99
th percentile of the upper reference limit) 
together with evidence of myocardial ischemia with at 
least one of the following: symptoms of ischemia, ECG 
change indicative of new ischemia, and imaging evidence 
of new loss of viable myocardium or new regional wall 
motion abnormality. Stroke was defined as a brain lesion 
on MRI or CT within 72 hours after the onset of neu-
rological deficits. Stent thrombosis was defined as defi-
nite or probable stent thrombosis according to the cri-
teria of the Academic Research Consortium (ARC).
11) 
Any death for which the cause was not determined to 
have a definitive non-cardiac origin was classified as a 
cardiac death. MACCE was defined as cardiac death, 
non-fatal myocardial infarction, stroke, stent thrombosis, 
coronary bypass surgery, or TLR. Bleeding rates were also 
defined based on the TIMI bleeding classification.
12) 
TIMI major bleeding was defined as intracranial hemor-
rhage or bleeding, with a hemoglobin decrease of >5 
g/dL or a hematocrit decrease of >15%.  
If a bleeding site was found, then TIMI minor bleeding 
was defined as a hemoglobin decrease of >3 g/dL or a he-
matocrit decrease of >10%; if no site was found, then it 
was defined as a hemoglobin decrease of >4 g/dL or a 
hematocrit decrease of >12%. TIMI minimal bleeding 
was defined as any clinically overt sign of hemorrhage 
associated with a hemoglobin decrease of <3 g/dL or a 
hematocrit decrease of 9%. Stent thrombosis was defined 
as definite or probable stent thrombosis according to the 
criteria of the ARC.
12) 
 
Statistical analysis 
Continuous variables were expressed as means±stan-
dard deviation (SD), and categorical variables were expre-
ssed as frequencies. An analysis of continuous variables 
was performed using Student’s t-test, and an analysis of 
categorical variables was performed using the chi-square 
test or Fisher’s exact test. Cox regression analysis was 
used to identify the factors affecting the incidence of 
MACCE following the implantation of DES in patients 
with AMI. All statistical analyses were performed using 
Statistical Package for Social Science (SPSS, SPSS Inc,  
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Chicago, IL, USA) for Windows, version 15.0. P<0.05 
were considered statistically significant. 
 
Results 
 
Clinical characteristics 
In Group I, the mean cilostazol administration period 
was 107.6±59.0 days, and 211 patients (51%) were pre-
scribed the drug for at least 90 days. 
The number of patients diagnosed with ST elevation 
myocardial infarction (STEMI) at the time of admission 
was 293 (70.9%) in Group I and 64 (55.7%) in Group II 
(p=0.002). However, there were no significant differences 
in mean age, sex, hypertension, diabetes mellitus, smok-
ing history, hyperlipidemia, family history of cardiovas-
cular disease, or past history of angina pectoris between 
the two groups. There were also no significant differen-
ces in Killip class III or IV ratio, glomerular filtration rate 
(GFR), or left ventricular ejection fraction (Table 1). 
 
Coronary angiographic findings and percutaneous 
coronary intervention 
In our coronary angiography series, infarction-related 
disease was found in the left anterior descending coro-
nary artery in 275 cases (52.1%), left circumflex artery 
in 80 cases (15.1%), right coronary artery in 164 cases 
(31.1%), and left main coronary artery in 9 cases (1.7%). 
There were no significant differences in these parameters 
between the two groups (Table 2). Single-vessel disease 
was seen in 62 (53.9%) patients in Group II and in 193 
(46.7%) patients in Group I (p=NS). Triple-vessel disease 
or left main disease was seen in 104 (25.2%) patients in 
Group I and in 21 (18.3%) patients in Group II (p=NS). 
The number of cases in which the degree of blood flow 
was TIMI flow 0 was 185 (44.8%) in Group I and 42 
(36.5%) in Group II. However, this difference was not 
statistically significant. TAXUS
® was the predominant 
DES used in Group I (83.5% vs. 73.0%, p=0.011), and 
Cypher
® was the predominant DES used in Group II 
(16.5% vs. 27.0%, p=0.011). There was no significant 
difference in the proportion of cases in which the stent 
was successfully placed between the two groups (99.8% 
vs. 98.9%, p=0.258). 
 
Major adverse cardiac and cerebrovascular events 
Of the total patients, 511 were available for follow-up 
observation, excluding eight patients (2.0%) in Group I 
and nine patients (7.8%) in Group II (Table 3). Two hun-
dred twenty-seven patients (55.5%) in Group I and 49 
patients (45.0%) in Group II underwent a 6-month fol-
low-up angiography (p=0.05). During the 6-month fol-
low-up period, non-fatal myocardial infarction developed 
in only one patient in Group II. ARC definite or probable 
stent thrombosis developed in ten patients (2.5%) in 
Group I and in three patients (2.8%) in Group II, but 
this difference was not statistically significant. Stroke 
developed in one patient each in Group I and in Group 
II (p=0.372). One patient in Group II underwent coro-
nary bypass surgery at two months following the proce-
dure. Cardiac death occurred in seven patients (1.7%) in 
Group I and in six patients (5.7%) in Group II (p=0.022). 
The cardiac death cases were as follows: three cases of ste-
nt thrombosis, one case of severe aortic valve stenosis, one 
case of aggravated heart failure, and two cases of cardiac 
death suspected on a telephone interview in Group I, 
and two cases of stent thrombosis and four cases of car-
diac death suspected on a telephone interview in Group 
II. The incidence of TLR was significantly lower in Group 
I than it was in Group II (5.7% vs. 11.5%, p=0.035). The 
incidence of MACCE within the 6-month period was 
Table 1. Baseline characteristics of triple (group I) and dual (group II) anti-platelet therapy
  Group I (n=413)  Group II (n=115)  p 
Age (years)  61.8±11.73 61.1±11.71 0.586 
Gender, male (%)  306 (74.1)  89 (77.4)  0.471 
Hypertension (%)  193 (46.7)  45 (39.1)  0.147 
Diabetes (%)  065 (15.7)  13 (11.3)  0.236 
Current smoker (%)  186 (45.0)  63 (54.8)  0.073 
Dyslipidemia (%)  17 (4.1)  5 (4.3)  0.912 
Family Hx of CAD (%)  20 (4.8)  7 (6.1)  0.592 
Hx of angina (%)  181 (43.8)  57 (49.6)  0.274 
Killip class (%)       
I or II  371 (89.8)  106 (92.2)  0.452 
III or IV  042 (10.2)  09 (7.8)  0.452 
Creatinine clearance (mL/min)  70.6±30.1 75.1±34.1 0.175 
Ejection fraction, (%)  55.6±11.8 54.9±11.0 0.571 
Diagnosis (%)       
STEMI  293 (70.9)  64 (55.7)  0.002 
NSTEMI  120 (29.1)  51 (44.3)  0.002 
Hx of CAD: history of coronary artery disease, STEMI: ST elevation myocardial infarction, NSTEMI: non-ST elevation myocardial infarction 
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also significantly lower in Group I than it was in Group 
II (7.9% vs. 16.0%, p=0.011). Two months following dis-
charge, subarachnoid hemorrhage developed in one pa-
tient in Group II. However, there were no significant dif-
ferences in the incidences of TIMI major or minor ble-
eding between the two groups (Table 4). 
 
Subgroup analyses 
Subgroup analyses were performed based on such pa-
rameters as lesion severity, ST-segment elevation, and the 
type of DES used. In accordance with the ACC/AHA 
lesion classification, in the simple lesions (type A or B1), 
there were no significant differences in the clinical events 
between the two groups. However, in the complex lesions 
(type B2 or C), the incidences of TLR and MACCE were 
significantly lower in Group I than they were in Group 
II (6.0% vs. 14.9%, p=0.012; 8.8% vs. 17.1%, p=0.037) 
(Table 5). 
In patients diagnosed with non-STEMI, the incidences 
of TLR and MACCE within a recent 6-month period 
were significantly lower in Group I than they were in 
Group II (4.3% vs. 19.1%, p=0.002; 5.2% vs. 20.4%, 
p=0.003). However, in patients diagnosed with STEMI, 
there were no significant differences between the two 
Table 2. Coronary angiographic findings and procedural characteristics in triple triple (group I) and dual (group II) anti-platelet therapy group
  Group I (n=413)  Group II (n=115)  p 
Infarct-related artery (%)       
LAD  209 (50.6)  66 (57.4)  0.198 
LCX  064 (15.5)  16 (13.9)  0.675 
RCA  134 (32.4)  30 (26.1)  0.192 
LM  06 (1.5)  3 (2.6)  0.417 
Involved vessel number (%)       
Single vessel  193 (46.7)  62 (53.9)  0.173 
Two vessel  116 (28.1)  32 (27.8)  0.956 
Three vessel or LM disease  104 (25.2)  21 (18.3)  0.123 
ACC/AHA classification (%)       
A or B1  125 (30.3)  32 (27.8)  0.613 
B2 or C  288 (69.7)  83 (72.2)  0.613 
Pre-PCI TIMI flow grade (%)       
0  185 (44.8)  42 (36.5)  0.113 
I  23 (5.6)  11 (9.6)  0.123 
II  104 (25.2)  33 (28.7)  0.447 
III  101 (24.5)  29 (25.2)  0.867 
Type of DES used (%)       
TAXUS
®  345 (83.5)  84 (73.0)  0.011 
Cypher
®  068 (16.5)  31 (27.0)  0.011 
Use of gylcoprotein IIb/IIIa inhibitor  142 (34.4)  42 (36.5)  0.670 
Successful PCI (%)  401 (99.8)  92 (98.9)  0.258 
LAD: left anterior descending artery, LCX: left circumflex artery, RCA: right coronary artery, LM: left main, ACC/AHA: American College of 
Cardiology/American Heart Association, PCI: percutaneous coronary intervention, TIMI: Thrombolysis In Myocardial Infarction, DES: drug-
eluting stent, LM: let main artery 
 
Table 3. Six-month clinical outcomes of triple (group I) and dual 
(group II) anti-platelet therapy group 
  Group I 
(n=405) 
Group II 
(n=106) 
p 
Cardiac death (%)  07 (1.7)  6 (5.7)  0.022 
Non-cardiac death (%)  00 (0.0)  1 (0.9)  0.207 
CVA (%)  01 (0.2)  1 (0.9)  0.372 
Stent thrombosis (%)  11 (2.7)  3 (2.8)  0.999 
Non-fatal AMI (%)  07 (1.7)  2 (1.9)  0.999 
Bypass surgery (%)  00 (0.0)  1 (0.9)  0.207 
TLR (%)  23 (5.7)  12 (11.3)  0.041 
MACCE (%)  32 (7.9)  17 (16.0)  0.011 
AMI: acute myocardial infarction, CVA: cerebrovascular accident,
TLR: target lesion revascularization, MACCE: major adverse cardiac
and cerebrovascular events 
 
Table 4. Bleeding complications after triple (group I) and dual 
(group II) anti-platelet therapy 
  Group I 
(n=413) 
Group II 
(n=115) 
p 
Degree of bleeding according to 
TIMI criteria (%) 
    
Major  00 (0.0)  1 (0.9)  0.218 
Minor  00 (0.0)  0 (0.0)  1.000 
Minimal  07 (1.7)  1 (0.9)  0.999 
Large-sized hematoma  ≥5 cm  16 (3.9)  8 (7.0)  0.160 
Small-sized hematoma <5 cm  38 (9.2)  6 (5.2)  0.172 
Need for blood transfusion  19 (4.6)  4 (3.5)  0.797 
TIMI: thrombolysis in myocardial infarction 
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groups (Table 5). 
In the Cypher
® stent group, there were no significant 
differences in the incidences of clinical events between 
Groups I and II. However, in the TAXUS
® stent group, 
the incidences of TLR and MACCE within a recent 6-
month period were significantly lower in Group I than 
they were in Group II (5.3% vs. 15.6%, p=0.002; 7.6% 
vs. 20.8%, p=0.001) (Table 5). 
 
Independent predictors for major adverse cardiac 
and cerebrovascular events 
Cox proportional regression analysis was performed to 
identify predictors of MACCE. Variables included age, 
sex, hypertension, diabetes mellitus, hyperlipidemia, a 
past history of smoking, a family history of cardiovascular 
disease, a past history of angina pectoris, left ventricular 
ejection fraction, creatinine clearance, Killip classification, 
classification of ACC/AHA lesions, ST-segment elevation, 
the number of diseased vessels, the type of DES used, 
and triple anti-platelet therapy. Independent predictors 
for MACCE in AMI patients undergoing DES implan-
tation included Killip class III or IV [hazard ratio (HR)= 
3.382; 95% confidence interval (CI)=1.384-8.262, p= 
0.007] and triple anti-platelet therapy (HR=0.436; 95% 
CI=0.203-0.933, p=0.017) (Table 6). 
 
Discussion 
 
This study was conducted in order to evaluate the effect 
of triple anti-platelet therapy following DES implantation 
in AMI patients. Our study showed that, although there 
were no significant differences in non-fatal myocardial 
infarction, stroke, or stent thrombosis between the group 
receiving triple anti-platelet therapy and the group receiv-
ing dual anti-platelet therapy, the incidences of cardiac 
death and TLR were significantly lower in the group re-
ceiving triple anti-platelet therapy. These findings indicate 
that triple anti-platelet therapy was effective in lowering 
the incidence of MACCE. It was particularly effective in 
lowering the incidence of TLR in patients with complex 
lesions and those diagnosed with non-STEMI. 
Recent studies have shown that DES significantly re-
duces repeat target-vessel revascularization in patients with 
Table 5. Six-month clinical outcomes on subgroup analysis
  Group I  Group II  p 
Patients with ACC/AHA A 
or B1 lesions (%) 
N=122 
 
N=30 
 
 
Cardiac death  0 (0.0)  3 (10.0)  0.007 
Non-cardiac death  0 (0.0)  0 (0.0)  1.000 
CVA  0 (0.0)  1 (3.3)  0.197 
Stent thrombosis  1 (0.8)  0 (0.0)  0.999 
Non-fatal AMI  1 (0.8)  0 (0.0)  0.999 
Bypass surgery  0 (0.0)  0 (0.0)  1.000 
TLR  6 (4.9)  1 (3.3)  0.999 
MACCE  7 (5.7)  4 (13.3)  0.229 
Patients with ACC/AHA B2 
or C lesions (%) 
N=283 
 
N=76 
 
 
Cardiac death  7 (2.5)  3 (3.9)  0.447 
Non-cardiac death  0 (0.0)  1 (1.3)  0.212 
CVA  1 (0.4)  0 (0.0)  0.999 
Stent thrombosis  9 (3.2)  3 (3.9)  0.724 
Non-fatal AMI  6 (2.1)  2 (2.6)  0.678 
Bypass surgery  0 (0.0)  1 (1.3)  0.212 
TLR  17 (6.0)  11 (14.9)  0.012 
MACCE  25 (8.8)  13 (17.1)  0.037 
NSTEMI group (%)  N=116 N=49  
Cardiac death  1 (0.9)  3 (6.1)  0.079 
Non-cardiac death  0 (0.0)  1 (2.0)  0.297 
CVA  0 (0.0)  0 (0.0)  1.000 
Stent thrombosis  2 (1.7)  2 (4.1)  0.582 
Non-fatal AMI  1 (0.9)  1 (2.0)  0.507 
Bypass surgery  0 (0.0)  0 (0.0)  1.000 
TLR  5 (4.3)  9 (19.1)  0.002 
MACCE  6 (5.2)  10 (20.4)  0.003 
STEMI group (%)  N=289 N=57  
Cardiac death  6 (2.1)  3 (5.3)  0.171 
Non-cardiac death  0 (0.0)  0 (0.0)  1.000 
CVA  1 (0.3)  1 (1.8)  0.303 
Stent thrombosis  8 (2.8)  1 (1.7)  0.999 
Non-fatal AMI  6 (2.1)  1 (1.8)  0.999 
Bypass surgery  0 (0.0)  1 (1.8)  0.165 
TLR  18 (6.2)  3 (5.3)  0.999 
(MACCE)  26 (9.0)  7 (12.3)  0.440 
Use of Cypher
® stent (%)  N=65 N=29  
Cardiac death  1 (1.5)  0 (0.0)  0.171 
Non-cardiac death  0 (0.0)  0 (0.0)  1.000 
CVA  0 (0.0)  0 (0.0)  1.000 
Stent thrombosis  3 (4.6)  1 (3.4)  0.999 
Non-fatal AMI  2 (3.1)  1 (3.4)  0.999 
Bypass surgery  0 (0.0)  0 (0.0)  1.000 
TLR  0 (0.0)  5 (7.7)  0.319 
(MACCE)  6 (9.2)  1 (3.4)  0.431 
Use of TAXUS
® stent (%)  N=340 N=77  
Cardiac death  6 (1.8)  6 (7.8)  0.004 
Non-cardiac death  0 (0.0)  1 (1.3)  0.185 
CVA  1 (0.3)  1 (1.8)  0.336 
Table 5. Continued
  Group I  Group II  p 
Stent thrombosis (%)  7 (2.1)  2 (2.6)  0.674 
Non-fatal AMI (%)  5 (1.5)  1 (1.3)  0.999 
Bypass surgery  0 (0.0)  1 (1.3)  0.185 
TLR (%)  18 (5.3)  12 (15.6)  0.002 
MACCE (%)  26 (7.6)  16 (20.8)  0.001 
ACC/AHA: American College of Cardiology/American Heart As-
sociation, CVA: cerebrovascular accident, AMI: acute myocardial in-
farction, TLR: target lesion revascularization, MACCE: major ad-
verse cardiac and cerebrovascular events, NSTEMI: non-ST elevation
myocardial infarction, STEMI: ST elevation myocardial infarction 
  
 
Keun-Ho Park, et al.·195 
AMI and also significantly lowers the two-year mortali-
ty.
13) However, varying opinions still exist regarding the 
use of DES in patients with AMI, as an off-label indica-
tion.
14) The rate of in-stent restenosis is markedly decreas-
ed with DES compared to BMS. Some investigators 
have reported that DESs are relatively free from compli-
cations of stent thrombosis,
11)15) but this opinion is still 
controversial. To avoid this complication, medical treat-
ment plays a crucial role in addition to the development 
of novel stents
16)17) and the development of technology 
for stent implantation. 
In the setting of percutaneous intervention, dual anti-
platelet agents including aspirin and clopidogrel can pre-
vent the occurrence of acute or subacute stent thrombosis 
and have been reported to lower the incidence of major 
adverse cardiac events.
18)19) Therefore, at present, the use 
of dual anti-platelet agents prior to or following the pro-
cedure has been accredited as the standard treatment. 
Cilostazol selectively inhibits phosphodiesterase type 
3, which is released from the platelet, and thereby raises 
the intracellular concentration of cyclic adenosine mono-
phosphate (cAMP) and calcium. This leads to suppression 
of platelet aggregation and relaxation of vascular smooth 
muscle cells, which ultimately have a vasodilatory effe-
ct.
20)21) Cilostazol has been reported to have a greater 
degree of anti-platelet effect compared to aspirin or tic-
lopidine.
22) Concomitant use of cilostazol with aspirin 
and clopidogrel has also been reported to suppress the 
expression of P-selectin, the indicator of platelet activity, 
and to thereby strengthen the anti-platelet effect.
23) 
In addition to its anti-platelet effects, cilostazol is kno-
wn to reduce in-stent restenosis in the primary lesions 
of native vessels.
7)24) This effectiveness is associated with 
the inhibitory effect of cilostazol on the proliferation of 
vascular smooth muscle cells.
25)26) The following patho-
physiology has been proposed to explain this occurrence. 
Expression of the p53 gene is enhanced, and thereby the 
progression of the cell cycle is inhibited and apoptosis is 
induced. Hepatocyte growth factor (HGF) secretion is 
enhanced, and vascular endothelial cell function is im-
proved. Hence, restenosis is improved following angiopla-
sty.
27) 
This anti-proliferative effect plays a crucial role in 
reducing in-stent restenosis, along with the anti-platelet 
and vasodilatory effects. Therefore, triple anti-platelet th-
erapy including cilostazol has been reported to signifi-
cantly reduce in-stent restenosis in patients with diabetes 
mellitus or long lesions, who are at high risk of resteno-
sis.
9)10)28) 
Myocardial infarction is also associated with coronary 
artery stenosis due to severe atherosclerosis or coronary 
occlusion due to atherosclerotic plaque rupture.
29) Res-
tenosis remains problematic following stent implantation. 
In this study, we showed that triple anti-platelet therapy 
including cilostazol reduced the incidence of TLR in pa-
tients with myocardial infarction (relative risk reduction: 
50%). These findings indicate that cilostazol has an anti-
proliferative effect, even in patients with myocardial in-
farction. 
In our study, subgroup analysis showed that triple anti-
platelet therapy significantly lowered the incidence of 
TLR in ACC/AHA type B2 or C lesions compared to 
ACC/AHA type A or B1 lesions, and in patients diag-
nosed with non-STEMI compared to patients diagnosed 
Table 6. Independent predictors of 6-month MACCE 
Variables  HR  95.0% CI  p 
Killlip III or IV on admission  3.382  1.384–8.262  0.007 
Triple antiplatelet therapy  0.436  0.203–0.933  0.033 
Ejection fraction  0.979  0.950–1.008  0.154 
Family Hx of CAD  1.200  0.561–2.565  0.163 
Single vessel disease  0.596  0.273–1.299  0.193 
Diagnosed STEMI  1.200  0.561–2.565  0.221 
ACC/AHA B2 or C lesions  1.586  0.728–3.455  0.245 
Current smoker  1.144  0.698–3.390  0.285 
Female gender  1.487  0.636–3.478  0.360 
Dyslipidemia 0.392  0.046–3.315  0.390 
Diabetes 1.347  0.532–3.412  0.529 
Use of TAXUS
® stent  1.294  0.505–3.317  0.591 
Age 0.990  0.952–1.029  0.599 
Hypertension 0.829  0.394–1.747  0.623 
Creatinine clearance  0.998  0.998–1.013  0.827 
Three vessel or LM disease  0.917  0.398–2.114  0.840 
Hx of angina  1.065  0.533–2.129  0.859 
MACCE: major adverse cardiac and cerebrovascular events, HR: hazard ratio, CI: confidence interval, Hx of CAD: history of coronary artery di-
sease, STEMI: ST elevation myocardial infarction, ACC/AHA: American College of Cardiology/American Heart Association, LM: let main artery 
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with STEMI (Table 4). These findings indicate that the 
anti-proliferative effect of cilostazol is greater in more 
severe atherosclerotic lesions. This is also demonstrated 
by the fact that the incidence of TLR was decreased in 
NSTEMI (where atherosclerosis is more prevalent and 
there are more AC/AHA type B2 or C lesions) compared 
to STEMI (where there are more lesions with thrombotic 
total occlusion). However, this merits further study. The 
incidence of TLR was significantly lower in the TAXUS
® 
stent group compared to the Cypher
® stent group. This 
finding also merits further study, because the number 
of enrolled patients who had Cypher
® stents was much 
smaller. 
The incidence of stent thrombosis has been reported to 
increase in cases in which primary stent implantation is 
performed for AMI.
30) Lee et al.
8) reported that triple anti-
platelet therapy including cilostazol significantly lowered 
the incidence of stent thrombosis following stent implan-
tation. In our study, a total of 13 patients (2.5%) had 
definite or probable stent thrombosis. Of these, nine 
patients were diagnosed with STEMI and underwent 
DES implantation. There was no significant difference 
in the incidence of stent thrombosis between the triple 
anti-platelet therapy group and the dual anti-platelet 
therapy group (2.5% vs. 2.8%, p=0.738). Considering 
that the triple anti-platelet therapy group had a greater 
number of patients with STEMI who had a greater th-
rombotic burden, we believe triple anti-platelet therapy 
offers an effective treatment for the prevention of stent 
thrombosis. 
Cilostazol therapy was not associated with any adverse 
effects, such as TIMI major hemorrhage. This implies 
that triple anti-platelet therapy following DES implanta-
tion is safe. 
Our study was conducted in patients to whom cilo-
stazol was administered for more than one month. In 
approximately 51% of the patients, however, cilostazol 
was administered for more than three months. A mini-
mal treatment period of one month is not sufficient for 
determining if cilostazol is an effective drug. Hence, 
further large-scale studies are warranted to examine the 
appropriate period of cilostazol treatment. 
The greatest limitation of our study is that it was con-
ducted as a single-center, retrospective, non-randomized, 
comparative study. Furthermore, regular follow-up cor-
onary angiography was performed in only approxima-
tely 53% of the patients. TLR were performed based on 
the operators’ judgment of regular follow-up coronary 
angiography, rather than on ischemic symptoms. Because 
of this, the possibility of selection bias cannot be comple-
tely ruled out. Intravascular ultrasonography, which is 
capable of assessing in-stent restenosis and neointimal 
hyperplasia more accurately, was not performed in all 
the patients. 
The current study is significant, however, in that it 
included a relatively large number of patients and the 
incidence of TLR was further decreased. This occurred 
despite the presence of an “ocular-stenotic reflex” in the 
triple anti-platelet therapy group secondary to the higher 
prevalence of follow-up coronary angiography in this 
group. 
In conclusion, triple anti-platelet therapy following 
DES implantation in AMI patients was safe and effec-
tive in reducing the occurrence of TLR and MACCE 
within six months, as compared to dual anti-platelet the-
rapy. This reduction was particularly significant in pa-
tients with complex lesions and those diagnosed with 
non-STEMIs. 
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